Aug 3 (Reuters) – Supernus Pharmaceuticals and Indivior Pharmaceuticals said on Monday they had agreed to an all-stock merger that would create a company with about $2.2 billion in annual revenue and a portfolio of medicines for neurological, psychiatric and addiction-related conditions. Shares of Supernus were up over 20% and Indivior shares were nearly 10% […]
Health
Supernus, Indivior merge to strengthen neuroscience drug portfolio
Audio By Carbonatix
Aug 3 (Reuters) – Supernus Pharmaceuticals and Indivior Pharmaceuticals said on Monday they had agreed to an all-stock merger that would create a company with about $2.2 billion in annual revenue and a portfolio of medicines for neurological, psychiatric and addiction-related conditions.
Shares of Supernus were up over 20% and Indivior shares were nearly 10% higher in premarket trading.
• The combined company will have 11 marketed medicines for conditions including opioid addiction, epilepsy, migraine, Parkinson’s disease and attention-deficit hyperactivity disorder. The companies expect about $125 million in annual cost savings.
• Supernus shareholders will receive 1.5401 Indivior shares for each share held. Indivior shareholders will own about 56.5% of the combined company, while Supernus shareholders will hold the rest.
• Indivior shareholders will also receive a $1 billion special cash dividend immediately before the merger closes. The companies plan to fund $650 million of the dividend with new debt and the rest with existing cash.
• The combined company will be named Supernus, Inc and led by Supernus CEO Jack Khattar, the companies said. Together they are expected to have about $878 million in net debt.
• The company will have an eight-member board that will include four directors from each company.
• The merger is expected to close in the fourth quarter of 2026, subject to shareholder and regulatory approvals and other closing conditions.
(Reporting by Kunal Das in Bengaluru; Editing by Shinjini Ganguli)